30 / 43
‘Ultimately, a sustainable solution to the challenge of tissue-agnostic
biomarkers will require collaboration across companies and some type
of flexible trial design’
|
|
30 / 43
30 / 43
‘Ultimately, a sustainable solution to the challenge of tissue-agnostic
biomarkers will require collaboration across companies and some type
of flexible trial design’